Last updated: April 25, 2026
What Are the Known Suppliers for Tioconazole (Topical Antifungal)?
Tioconazole is a small-molecule azole antifungal used in topical formulations (commonly creams, ointments, and sometimes pessaries). Supplier coverage depends on the specific formulation, site qualification status, and whether buyers source active pharmaceutical ingredient (API), intermediates, or finished dosage forms. Public supplier visibility also varies by country and regulatory track record.
API suppliers (tioconazole) and commercial sources
The table below lists suppliers that appear in public catalogs/market coverage for tioconazole API and related commercial supply lines.
| Supplier / source type |
What they supply |
Geography (public signal) |
Typical documentation buyers request |
| Chemical catalog distributors (global) |
Tioconazole (API) or branded bulk chemical listings |
Global |
CoA, CoC, SDS, impurity profile, specification sheet |
| Specialty chemical manufacturers (API-focused) |
Tioconazole or tioconazole-grade material |
Asia, EU, or US-based coverage |
GMP letter, DMF/CEP status (if held), release specs |
| Contract manufacturing ecosystems (API-to-finished) |
Tioconazole API plus formulation capability |
Multi-region |
GMP manufacturing record, stability protocol, validation package |
Where tioconazole suppliers show up in procurement workflows
For buyers, tioconazole supply typically splits into three channels, each with different due diligence requirements.
-
API procurement (tioconazole active)
- Inputs: tioconazole API bulk lot supply
- Typical compliance: GMP for API, CoA with assay and impurities, particle size and polymorph statements if applicable
- Qualification: vendor audit, change control terms, analytical method alignment
-
Intermediate sourcing (azole synthesis supply chain)
- Inputs: upstream intermediates used in azole ring formation and side-chain build
- Typical compliance: impurity thresholds, residual solvent controls, defined impurity mapping to final API spec
-
Finished dosage form sourcing (if formulators skip API)
- Inputs: finished creams/ointments or pessaries
- Typical compliance: finished product GMP, regulatory dossier alignment, labeling/packaging standards
Which supplier categories matter most for business decisions?
**If you need commercial API supply, what matters?
Buyers generally prioritize:
- Quality system: GMP status for API and controlled change management
- Analytical certainty: CoA coverage for assay and key impurities
- Regulatory path: CEP/DMF availability where applicable
- Supply continuity: multi-lot availability, lead times, and second-source readiness
**If you need scale, what matters?
At scale, procurement teams tend to screen for:
- Batch reproducibility: impurity profile stability across lots
- Solvent and residual controls: alignment to spec limits
- Packaging and storage: humidity/temperature handling terms
- On-time delivery performance: acceptance criteria and contingency stock terms
Supplier due diligence checklist for tioconazole
Use this as a qualification template for any tioconazole supplier short list.
| Diligence area |
Evidence to request |
| GMP status |
API GMP certificate, manufacturing site scope |
| Quality documentation |
Latest CoA template, SDS, typical impurity profile |
| Regulatory support |
CEP/DMF status where held, ability to support regulatory submissions |
| Test coverage |
Assay method and impurity methods, LOQ and detection limits (where relevant) |
| Change control |
Written change control policy, notification timelines |
| Logistics |
Packaging compatibility, shelf-life statement, lead-time schedule |
| Lot traceability |
Lot-to-lot traceability, re-test and expiry policy |
What suppliers typically offer for tioconazole specifications
Public supplier catalogs commonly publish broad chemical-identification attributes; contract suppliers typically provide the detailed specification under NDA or in vendor onboarding packets.
Common spec types you should expect for tioconazole API:
- Assay
- Related substances / impurities
- Water content (if applicable)
- Residual solvents (if applicable)
- Appearance and particle attributes
- Heavy metals (if applicable)
- Microbiological controls (less common for API, but sometimes requested depending on compendial approach)
Market structure: why supplier names are hard to pin down publicly
Tioconazole is older and less visible than newer oncology or high-profile branded APIs. Many supply relationships are handled through:
- private distribution agreements,
- distributor resale channels,
- or regional sourcing with limited public transparency.
In practice, procurement teams usually confirm supplier identity via:
- CoA headers and lot documentation,
- GMP certificates,
- and regulatory dossier references tied to a manufacturer name.
Key Takeaways
- Tioconazole supply typically runs through three procurement channels: API, intermediates, and finished dosage forms.
- Supplier selection should be driven by GMP status, impurity/assay documentation, regulatory support (CEP/DMF if held), and lot traceability.
- Publicly visible supplier listings often do not reflect the final GMP manufacturer name; the decisive supplier identity comes from GMP certificates, CoA headers, and dossier alignment.
FAQs
1) Do tioconazole suppliers sell API and finished product?
Many suppliers sell tioconazole API through chemical distribution channels, while separate contract manufacturers often handle finished dosage forms. Some suppliers span both, but buyers should qualify the specific manufacturing site for the lot they receive.
2) What documents should an API supplier provide for tioconazole?
Typical onboarding requests include a CoA, SDS, GMP evidence for API manufacturing, impurity profile/specification sheet, and change control terms.
3) How do buyers verify the actual GMP manufacturer for tioconazole?
They match the lot CoA headers to the GMP certificate site name and confirm the manufacturing scope covering tioconazole API.
4) What quality risks matter most for tioconazole API?
Assay drift and impurity profile variation are the practical risks procurement focuses on, alongside residual solvent and water controls where specified.
5) Can buyers qualify a single-source tioconazole supplier?
Qualification standards usually require at least a contingency path. Even when a single supplier wins initial validation, continuity planning uses a second-source strategy to control supply disruption risk.
References
[1] European Medicines Agency. “T ioconazole” and related medicinal substance information in EMA resources. https://www.ema.europa.eu/
[2] US FDA. Substance and product information resources relevant to tioconazole-containing medicines. https://www.fda.gov/
[3] World Health Organization. General chemical and medicine quality guidance used for API/finished product supplier evaluation. https://www.who.int/
